Nav: Home

Significant decrease seen in prostate biopsy, radical prostatectomy procedures following recommendations

November 02, 2016

In a study published online by JAMA Surgery, Jim C. Hu, M.D., M.P.H., Joshua A. Halpern, M.D., M.S., of Weill Cornell Medicine, New York, and colleagues examined effects on practice patterns in prostate cancer diagnosis and treatment following the U.S. Preventative Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA) screening in 2012.

Prostate cancer is the most common nondermatologic malignancy among men in the United States, with an estimated 220,000 new cases and 27,540 deaths in 2015. Owing to its high incidence and the potential for cure with early detection, population-based screening programs were widely implemented in the United States during the 1990s. However, the USPSTF recommended against population-based PSA screening following a randomized clinical trial that showed no mortality benefit to PSA screening, and screening decreased significantly following this recommendation. Few studies have examined the downstream effects of the USPSTF recommendation on diagnostic and therapeutic prostate cancer practice patterns.

For this study, the researchers evaluated procedural volumes of certifying and recertifying urologists from 2009 through 2016 for variation in prostate biopsy and radical prostatectomy (RP) volume. The study included a representative sample of urologists across practice settings and nationally representative sample of all RP discharges. Operative case logs were obtained from the American Board of Urology and urologists performing at least 1 prostate biopsy (n = 5,173) or RP (n = 3,748) were identified.

The researchers found that following the USPSTF recommendation, median biopsy volume per urologist decreased from 29 to 21. After adjusting for physician and practice characteristics, biopsy volume decreased by 29 percent following 2012. Similarly, following the USPSTF recommendation, median RP volume per urologist decreased from 7 to 6, and in adjusted analyses, RP volume decreased 16 percent.

"These findings represent the direct downstream effects of the USPSTF recommendation. While the pendulum of prostate cancer screening continues to swing, a more extended vantage point is needed to evaluate the long-term consequences of the 2012 USPSTF recommendation with regard to stage at presentation, outcomes following treatment, and disease-specific mortality in prostate cancer. Because revision of the USPSTF recommendation is in progress, policy makers should weigh the downstream effects of the 2012 USPSTF recommendation and consider future unintended consequences," the authors write.
-end-
(JAMA Surgery. Published online November 2, 2016.doi:10.1001/jamasurg.2016.3987. This study is available pre-embargo at the For The Media website.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Prostate Cancer Articles:

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
More Prostate Cancer News and Prostate Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...